QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Relatlimab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Relatlimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Several patients develop similar acute reactions after receiving the same presentation. Which additional investigation is particularly warranted?

Review of batch, storage, preparation, infusion system and administration conditions Automatic attribution of every case to melanoma progression Removal of all immune-mediated events from signal detection Assessment limited to the patients' baseline thyroid function

Question 2 of 10 A patient develops elevated liver tests during treatment. Which follow-up plan best reflects the article's recommended approach?

Record immune-mediated hepatitis as confirmed without further investigation Obtain serial liver tests and evaluate viral infection, metastases, biliary obstruction, alcohol and concomitant medicines Stop investigation once bilirubin is initially normal Assess only the time elapsed since the most recent infusion

Question 3 of 10 Which statement best describes the significance of relatlimab being an IgG4 monoclonal antibody and biological medicinal product?

It makes batch and presentation information unnecessary It supports the need for product-specific quality information and traceability in safety investigations It means all adverse reactions are immunogenicity reactions It prevents the product from causing immune-mediated tissue injury

Question 4 of 10 Why should relatlimab safety cases generally be assessed at both product and active-substance levels?

Because the fixed-dose product contains two antibodies with distinct targets, while the clinical exposure and many adverse effects reflect the regimen as a whole Because relatlimab is chemically converted into nivolumab after administration Because the two antibodies are always administered on different days Because active-substance-level assessment is required only for product-quality complaints

Question 5 of 10 Why should an apparently resolved acute endocrine event not necessarily be closed as resolved?

Endocrine events are always caused by product contamination The patient may require long-term hormone replacement or specialist care despite improvement in the acute phase All endocrine events automatically become serious adverse reactions Checkpoint inhibitors cannot produce delayed effects

Question 6 of 10 Which scenario most clearly illustrates a failure to preserve treatment context?

Recording the product, both active substances, infusion date and prior checkpoint exposure Evaluating a liver-test abnormality using serial results and information on obstruction and concomitant medicines Assessing an adverse event solely against the latest infusion while omitting prior checkpoint therapy, tumour status and concomitant medicines Linking a product-quality complaint to the relevant batch and administration record

Question 7 of 10 A report describes radiological disease progression shortly after treatment initiation. What is the most appropriate pharmacovigilance interpretation?

Automatically classify it as treatment failure Automatically classify it as immune-mediated pseudoprogression Preserve the clinical and imaging assessment and evaluate progression in its disease and treatment context Exclude it because lack of efficacy is not relevant to pharmacovigilance

Question 8 of 10 Why can pooling first-line and heavily pretreated melanoma populations obscure a safety signal?

The populations may differ in baseline disease, prior therapies and susceptibility to adverse events First-line patients cannot experience immune-mediated events Heavily pretreated patients cannot receive fixed-dose combinations Pooling always increases the specificity of a signal

Question 9 of 10 Which data set is most important when investigating an acute reaction occurring during an infusion?

Only the patient's tumour stage and date of diagnosis Infusion rate, timing, vital signs, premedication, treatment and any preparation or batch information Only the patient's prior radiotherapy history Only the final outcome after hospital discharge

Question 10 of 10 What does the article mean by stating that the preferred term is only the starting point for an immune-mediated case?

Preferred terms should never be used in safety databases The coded term must be supplemented by clinical phenotype, objective findings, alternative diagnoses, treatment and outcome A preferred term automatically establishes mechanism and causality Only laboratory results are relevant after coding

QPPV.com

Professional Knowledge Assessment: Relatlimab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings